Never miss a trade again with the fastest news alerts in the world!
 This headline only article is a sample of real-time intelligence
 <a href="https://benzinga.grsm.io/headlineonlyarticles3398">Benzinga Pro</a> traders use to win in the markets everyday.
 Want the fastest, most accurate stock market intelligence? Want EXCLUSIVE stories originated by Benzinga reporters?
 <a href="https://benzinga.grsm.io/headlineonlyarticles3398">Join 10,000+ serious traders in the Benzinga Pro community!</a>

News

AbbVie And Xilio Therapeutics Announced A Collaboration And Option-to-license Agreement To Develop Novel Tumor-activated, Antibody-based Immunotherapies, As Per Which Xilio Will Receive $52.0M In Total Upfront Payments And Be Eligible To Receive Up To Around $2.1B In Total Contingent Payments For Option-related Fees And Milestones Plus Tiered Royalties - Xilio Therapeutics (NASDAQ:XLO), AbbVie (NYSE:ABBV)

Benzinga Newsdesk

Xilio Therapeutics

AbbVie

ABBV

AbbVie And Xilio Therapeutics Announced A Collaboration And Option-to-license Agreement To Develop Novel Tumor-activated, Antibody-based Immunotherapies, As Per Which Xilio Will Receive $52.0M In Total Upfront Payments And Be Eligible To Receive Up To Around $2.1B In Total Contingent Payments For Option-related Fees And Milestones Plus Tiered Royalties

Comments